Clinical trial · Interventional
Comparison of the Effect of Total Intravenous Anesthesia and Inhalation Anesthesia on Cancer Cell Cytotoxicity, Micrometastasis and Recurrence of Tumor in Patients Undergoing Breast Tumor Resection
NCT02089178CI-TRIAL-00037684terminatedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): The study costed more than expected, so the investigators decided to end it.
Summary
Brief summary (as posted)
The purpose of this study is to compare the effect of total intravenous anesthesia and inhalation anesthesia on cancer cell cytotoxicity, micrometastasis and recurrence of tumor in patients undergoing breast tumor resection. Using propofol-remifentanil in total intravenous anesthesia group and sevoflurane -remifentanil in inhalation anesthesia group.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| inhalation anesthesia | Procedure | — | UNRESOLVED |
| intravenous anesthesia | Procedure | — | UNRESOLVED |
| propofol-remifentanil | Drug | — | UNRESOLVED |
| sevoflurane-remifentanil | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- intravenous
- description
- the total intravenous anesthesia group
- interventionNames
- Procedure: intravenous anesthesia
- Drug: propofol-remifentanil
- type
- ACTIVE_COMPARATOR
- label
- inhalation
- description
- the inhalation anesthesia group
- interventionNames
- Procedure: inhalation anesthesia
- Drug: sevoflurane-remifentanil
Primary outcomes (1)
- measure
- number of NK cell
- timeFrame
- at 24 hour after surgery.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * patient between 20 and 65 of age with ASA physical status Ⅰ-Ⅲ * breast cancer patients with no sign of local invasion (adjacent organs) and distant metastasis revealed by imaging studies * surgery performed by the same surgical team Exclusion Criteria: * ASA physical status Ⅳ * hepatic and renal impairment * diabetes or other endocrine disorders * body mass index \> 35 kg/m2 * immune disorders or immunosuppressive therapy * steroid treatment in the last 6 months * inflammation
References
Publications (0)
Data not yet available
No reference posted for this study.